EMA Hails Success Of COVID-19 Multi-Regulator Collaboration
Executive Summary
The international COVID-19 collaborative assessment pilot, OPEN, helped regulators to reach broadly similar conclusions on vaccines and therapeutics and to avoid differences in labeling. However, most experts involved agreed there was room for improvement in some areas, particularly gaps between submissions to the different regulators.
You may also be interested in...
EU Joint Regulatory Assessment Project Bears Fruit In COVID-19
The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.
EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’
Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.